AVXL
Anavex Life Sciences
stockNASDAQ
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson's disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.36 | 2026-10-22 | -4.04% | 0.801 |
| 1M | 2.36 | 2026-09-29 | -44.70% | 0.675 |
| 3M | 2.49 | 2026-07-29 | -47.59% | 2.382 |
| 6M | 3.26 | 2026-04-29 | -59.97% | 1.802 |
| 1Y | 8.02 | 2025-10-29 | -83.73% | 1.843 |
| 2Y | 5.72 | 2024-10-29 | -77.17% | — |
| 5Y | 18.74 | 2021-10-29 | -93.04% | 1.707 |
Anavex Life Sciences (NASDAQ:AVXL) stock price today is $1.31, and today's volume is 742,451. AVXL is up 0.385% today. The 30 day average volume is 1.28M. AVXL market cap is $120.97M with 92.70M shares outstanding.